Department of Health and Social Care written question – answered on 22nd February 2019.

Alert me about debates like this

Photo of Daniel Zeichner Daniel Zeichner Labour, Cambridge

To ask the Secretary of State for Health and Social Care, what plans the Government has to work with the Joint Committee on Vaccination and Immunisation to establish a value assessment measure of antimicrobial resistance in the consideration of existing and new immunisation programmes.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The Joint Committee on Vaccination and Immunisation (JCVI) is aware that vaccination has an important role in controlling antimicrobial resistance but considers that current models are not sufficiently developed to fully estimate and quantify the potential impact of vaccines on the burden of antimicrobial resistance. Many of the potential benefits of vaccination in relation to antimicrobial resistance (AMR) cannot therefore be easily included in estimates of cost-effectiveness.

The JCVI has suggested that better tools need to be developed to estimate and quantify the potential impact of vaccines in reducing the long-term burden of AMR. This could then inform cost-effectiveness analyses. The National Institute of Health Research, Health Protection Research Unit, based at the London School of Hygiene and Tropical Medicine, is currently working on the development of such models.

As most resistant infections are healthcare associated, the new JCVI Healthcare Associated Infections Working Group, set up to review and provide preliminary advice to JCVI on the potential use of appropriate vaccines in the United Kingdom, will help to address this issue.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.